Taysha Gene Therapies (TSHA) to Release Quarterly Earnings on Thursday

Taysha Gene Therapies (NASDAQ:TSHA - Get Free Report) will likely be posting its Q1 2025 quarterly earnings results before the market opens on Thursday, May 15th. Analysts expect Taysha Gene Therapies to post earnings of ($0.08) per share and revenue of $1.48 million for the quarter.

Taysha Gene Therapies (NASDAQ:TSHA - Get Free Report) last issued its quarterly earnings results on Wednesday, February 26th. The company reported ($0.07) EPS for the quarter, beating the consensus estimate of ($0.08) by $0.01. The company had revenue of $2.02 million for the quarter, compared to the consensus estimate of $2.05 million. Taysha Gene Therapies had a negative net margin of 229.67% and a negative return on equity of 106.36%. On average, analysts expect Taysha Gene Therapies to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Taysha Gene Therapies Stock Up 1.4 %

NASDAQ TSHA traded up $0.03 during midday trading on Friday, hitting $2.13. 2,133,951 shares of the company traded hands, compared to its average volume of 2,815,250. Taysha Gene Therapies has a 52 week low of $1.05 and a 52 week high of $4.32. The company's 50-day simple moving average is $1.65 and its 200-day simple moving average is $1.81. The company has a debt-to-equity ratio of 0.48, a current ratio of 5.51 and a quick ratio of 5.51. The company has a market cap of $436.77 million, a PE ratio of 3.38 and a beta of 0.90.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on the stock. Needham & Company LLC reaffirmed a "buy" rating and set a $6.00 price objective on shares of Taysha Gene Therapies in a research note on Thursday, April 10th. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $7.00 target price on shares of Taysha Gene Therapies in a research note on Monday, April 28th. JMP Securities reaffirmed a "market outperform" rating and issued a $5.00 target price on shares of Taysha Gene Therapies in a research note on Monday, April 28th. Finally, Chardan Capital reissued a "buy" rating and set a $7.00 target price on shares of Taysha Gene Therapies in a research note on Wednesday, February 26th. Eight analysts have rated the stock with a buy rating, According to MarketBeat, Taysha Gene Therapies presently has an average rating of "Buy" and an average price target of $6.63.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.